SAb Biotherapeutics, Inc.
SAB Biotherapeutics is a leading biopharmaceutical company dedicated to developing human antibody therapeutics using advanced polyclonal antibody science. They utilize a unique platform technology called DiversitAb™ to produce fully human antibodies in large animals, such as genetically engineered cattle, to fight various diseases including infectious diseases, autoimmune disorders, and cancers. Their mission is to change lives impacted by diseases like type 1 diabetes, Ebola, MERS, influenza, and more, through innovative, scalable, and rapid-response antibody therapies. The company is also pioneering the use of genetically engineered animals to produce human antibodies, which could provide scalable treatments for infectious diseases such as Ebola, Zika, and MERS, and is recognized by WHO as a promising platform technology.
Industries
Nr. of Employees
medium (51-250)
SAb Biotherapeutics, Inc.
Patents
Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
US-11975066-B2
View Details
Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
US-11975066-B2
View DetailsProducts
Disease-modifying immunotherapy candidate for Type 1 Diabetes
A therapeutic immunotherapy intended to modify autoimmune processes in Type 1 Diabetes with the objective of preserving insulin-producing beta cell function and delaying disease progression.
Human polyclonal antibody therapeutics for emerging infectious diseases
Pipeline of human polyclonal antibody candidates generated from immunized production animals against multiple infectious disease targets, intended for therapeutic treatment or post-exposure prophylaxis.
Disease-modifying immunotherapy candidate for Type 1 Diabetes
A therapeutic immunotherapy intended to modify autoimmune processes in Type 1 Diabetes with the objective of preserving insulin-producing beta cell function and delaying disease progression.
Human polyclonal antibody therapeutics for emerging infectious diseases
Pipeline of human polyclonal antibody candidates generated from immunized production animals against multiple infectious disease targets, intended for therapeutic treatment or post-exposure prophylaxis.
Services
End-to-end service from antigen immunization of genetically engineered large animals through plasma collection, purification and release of clinical-grade IgG suitable for human trials.
Conduct of neutralization assays and efficacy studies in small-animal infection models to demonstrate protective activity of antibody preparations prior to clinical translation.
Manufacture and supply of clinical-grade antibody material and related chemistry, manufacturing and controls (CMC) support to enable early-phase clinical trials.
Site planning, construction integration and operational setup for greenfield facilities configured for housing production animals, plasma collection, veterinary operations and on-site biomanufacturing.
End-to-end service from antigen immunization of genetically engineered large animals through plasma collection, purification and release of clinical-grade IgG suitable for human trials.
Conduct of neutralization assays and efficacy studies in small-animal infection models to demonstrate protective activity of antibody preparations prior to clinical translation.
Manufacture and supply of clinical-grade antibody material and related chemistry, manufacturing and controls (CMC) support to enable early-phase clinical trials.
Site planning, construction integration and operational setup for greenfield facilities configured for housing production animals, plasma collection, veterinary operations and on-site biomanufacturing.
Expertise Areas
- Polyclonal antibody therapeutics
- Large-animal bioproduction for biologics
- Rapid-response therapeutic development for emerging pathogens
- Antigen design and immunization strategies
Key Technologies
- Genetically engineered large-animal antibody production
- Plasma collection and IgG purification
- Nucleic acid (DNA) and recombinant vaccine immunization
- Preclinical in vivo infection models (mouse, hamster)
News & Updates
SAB to Host Virtual R&D Day
SAB Biotherapeutics announced a virtual research and development day scheduled for October 13, 2021.
First Patient Dosed in Phase 3 NIH ACTIV-2 Trial for SAB-185
SAB announced the dosing of the first patient in a Phase 3 trial evaluating SAB-185 for COVID-19 treatment.
Progress on MERS treatment with SAB-301
SAB announced that Phase I clinical trials are underway for its MERS antibody treatment SAB-301.
Contract with BARDA for MERS treatment
SAB received a contract from BARDA to advance the development of SAB-301 for MERS-CoV.
Recognition by WHO as a top platform technology
SAB's DiversitAb™ platform was recognized by WHO as a promising platform for infectious disease response.
Researchers use genetically engineered cattle to produce human antibodies for infectious diseases.
SAB to Host Virtual R&D Day
SAB Biotherapeutics announced a virtual research and development day scheduled for October 13, 2021.
First Patient Dosed in Phase 3 NIH ACTIV-2 Trial for SAB-185
SAB announced the dosing of the first patient in a Phase 3 trial evaluating SAB-185 for COVID-19 treatment.
Progress on MERS treatment with SAB-301
SAB announced that Phase I clinical trials are underway for its MERS antibody treatment SAB-301.
Contract with BARDA for MERS treatment
SAB received a contract from BARDA to advance the development of SAB-301 for MERS-CoV.
Recognition by WHO as a top platform technology
SAB's DiversitAb™ platform was recognized by WHO as a promising platform for infectious disease response.
Researchers use genetically engineered cattle to produce human antibodies for infectious diseases.